Rabbit Recombinant Monoclonal FABP4 antibody - conjugated to HRP. Suitable for IHC-P, WB and reacts with Human samples.
pH: 7.4
Preservative: 0.1% Proclin 300 Solution
Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
IHC-P | WB | |
---|---|---|
Human | Tested | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/50 | Notes Perform heat-mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/5000 | Notes - |
Select an associated product type
Lipid transport protein in adipocytes. Binds both long chain fatty acids and retinoic acid. Delivers long-chain fatty acids and retinoic acid to their cognate receptors in the nucleus.
Adipocyte lipid-binding protein, Adipocyte-type fatty acid-binding protein, Fatty acid-binding protein 4, ALBP, A-FABP, AFABP, FABP4
Rabbit Recombinant Monoclonal FABP4 antibody - conjugated to HRP. Suitable for IHC-P, WB and reacts with Human samples.
pH: 7.4
Preservative: 0.1% Proclin 300 Solution
Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Fatty acid-binding protein 4 (FABP4) also known as aP2 is a member of the fatty acid-binding protein family. It predominantly exists in adipocytes and macrophages serving an important role in lipid metabolism and transport. FABP4 facilitates the binding and transport of long-chain fatty acids and other hydrophobic molecules within cells. The molecular weight of FABP4 is approximately 14-15 kDa. It exhibits high expression levels in adipose tissue and is inducible in macrophages under certain conditions.
This protein participates in the regulation of lipid homeostasis and energy metabolism. FABP4 is part of the lipid-binding protein family that helps maintain fatty acid equilibrium within cells. By controlling the transport and signaling of lipids FABP4 impacts lipid storage insulin sensitivity and inflammation processes. Its activity is not confined to a specific multimeric complex yet it interacts with other proteins to exert its functions contributing to significant metabolic pathways in the body.
FABP4 plays essential roles in the regulation of metabolic and inflammatory signaling pathways. It is intricately involved in the peroxisome proliferator-activated receptor gamma (PPARγ) pathway where it modulates adipose tissue development and glucose metabolism. In addition FABP4 has connections with the c-Jun N-terminal kinase (JNK) signaling pathway influencing stress and inflammatory responses. Interactions with these pathways place FABP4 at a link with proteins like PPARγ and JNK essential for cellular metabolic balance and responses to metabolic stress.
Researchers connect FABP4 to conditions such as obesity and type 2 diabetes. Its expression levels correlate with insulin resistance and metabolic syndrome making it a target of interest in these metabolic disorders. FABP4 interacts with other proteins like adiponectin which is important in modulating glucose levels and fatty acid breakdown. Understanding FABP4's role in these pathways can facilitate the development of therapeutic strategies aimed at targeting metabolic dysfunctions associated with obesity and diabetes.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
IHC image of FABP4 staining in a section of formalin-fixed paraffin-embedded normal human breast*, performed on a Leica BOND™. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20mins. The section was then incubated with ab216528, 1/50 dilution, for 15 mins at room temperature. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX. The inset negative control image is taken from an identical assay without primary antibody.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.
*Tissue obtained from the Human Research Tissue Bank, supported by the NIHR Cambridge Biomedical Research Centre
This blot was produced using a 4-12% Bis-tris gel under the MES buffer system. The gel was run at 200V for 35 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 2% Bovine Serum Albumin before being incubated with ab216528 overnight at 4°C. Antibody binding was visualised using ECL development solution ECL Substrate Kit (High Sensitivity) ab133406.
All lanes: Western blot - HRP Anti-FABP4 antibody [EPR3579] (ab216528) at 1/5000 dilution
Lane 1: Human Adipose at 10 µg
Lane 2: Heart (Human) Tissue Lysate - adult normal tissue at 10 µg
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 15 kDa
Observed band size: 15 kDa
Exposure time: 5s
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com